The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments

D Serrano, S Torrado… - Current Drug …, 2012 - ingentaconnect.com
Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs
undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 …
被引用次数：46 相关文章 所有 4 个版本

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection

JC Yang, CJ Lin - Expert opinion on drug metabolism & toxicology, 2010 - Taylor & Francis
Importance of the field: Proton pump inhibitors (PPIs) are potent gastric acid inhibitors.
Therapies with a PPI and antibiotics are used to cure Helicobacter pylori (H. pylori) infection …
被引用次数：69 相关文章 所有 5 个版本
[PDF] jst.go.jp

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies

T Furuta, N Shirai, M Sugimoto, A Nakamura… - Drug metabolism and …, 2005 - jstage.jst.go.jp
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole,
esomeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. There …
被引用次数：437 相关文章 所有 7 个版本

CYP2C19 Pharmacogenomics Associated with Therapy of Helicobacter Pylori Infection And Gastro-Esophageal Reflux Diseases With A Proton Pump Inhibitor

T Furuta, M Sugimoto, N Shirai, T Ishizaki - Pharmacogenomics, 2007 - Taylor & Francis
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole and rabeprazole, are
metabolized by CYP2C19 in the liver. There are genetic differences in the activity of this …
被引用次数：120 相关文章 所有 7 个版本
[PDF] academia.edu

[PDF][PDF] Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism

A Ormeci, Z Emrence, B Baran, OM Soyer… - Eur Rev Med …, 2016 - academia.edu
Proton pump inhibitors (PPI) metabolism and pharmacokinetics are regulated by cytochrome
P450 enzymes in the liver. Cytochrome P450 2C19 (CYP2C19) polymorphism plays an …
被引用次数：20 相关文章 所有 7 个版本

Pharmacogenomics of proton pump inhibitors

T Furuta, N Shirai, M Sugimoto, K Ohashi… - …, 2004 - Taylor & Francis
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole,
esomeprazole, and pantoprazole, are metabolized by cytochrome P450 isoenzyme 2C19 …
被引用次数：187 相关文章 所有 7 个版本

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

T Sakai, N Aoyama, T Kita, T Sakaeda… - Pharmaceutical …, 2001 - Springer
Purpose. To predict the CYP2C19 genotype-dependence in anti-Helicobacter pylori (H.
pylori) therapy when lansoprazole or rabeprazole was used instead of omeprazole as a …
被引用次数：193 相关文章 所有 11 个版本

Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection?

SV Van Zanten, K Thompson - … journal of the American College of …, 2006 - journals.lww.com
There are variations in the CYP2C19 genotypes, that are important for the metabolism of
PPIs. Patients who are heterozygotes for the mutation, but especially homozygotes, have a …
被引用次数：11 相关文章 所有 5 个版本

Pharmacogenetics of the proton pump inhibitors: a systematic review

E Chong, MHH Ensom - Pharmacotherapy: The Journal of …, 2003 - Wiley Online Library
Cytochrome P450 (CYP) 2C19 mediates the major metabolic transformations of the proton
pump inhibitors (PPIs) omeprazole, pantoprazole, lansoprazole, esomeprazole, and …
被引用次数：169 相关文章 所有 6 个版本

Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.

T Furuta, N Shirai, K Ohashi… - Methods and findings in …, 2003 - europepmc.org
Current regimens for the eradication of Helicobacter pylori consist of a proton pump inhibitor
(PPI) plus one or two antibacterial agents, such as amoxicillin (AMPC), clarithromycin (CAM) …
被引用次数：36 相关文章 所有 8 个版本